April 23, 2009 - A new study shows that the SAVI applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices.

The research, led by radiation oncologists and surgeons at the Moores UCSD Cancer Center and Fort Myers, Florida-based 21st Century Oncology, also indicates that other complications – such as seromas, pockets of fluid that build with the use of internal radiation devices – are unlikely to occur.

That’s good news for those women with early-stage breast cancer who opt to have such devices inserted for their radiation therapy after breast-sparing lumpectomy surgery, said Catheryn Yashar, M.D., associate professor of radiation oncology at the UC San Diego School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center. Their use is increasing, she added, noting that the Moores UCSD Cancer Center was one of the first medical facilities in the country to offer SAVI.

SAVI, which consists of flexible catheters through which radiation is given, provides customized radiation therapy and minimizes exposure to healthy tissue after a woman has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes decide to give women internal radiation – a process called brachytherapy – with the goal of giving concentrated doses of radiation to areas of concern while avoiding healthy tissue.

In the study, researchers examined one-year follow-up data on 63 patients treated with the Food and Drug Administration-approved SAVI device. They found an infection rate that is less than half of the published rates associated with balloon brachytherapy methods, and rated overall cosmetic outcomes with SAVI as “excellent.” The results will be presented at the American Society of Breast Surgeon’s annual meeting in San Diego, April 24, 2009.

In addition, physicians were able to use the device’s many catheters to customize the radiation dose based on the woman’s needs, greatly minimizing radiation to the heart, lungs, ribs and skin, likely resulting in fewer complications, Yashar said. To date, there have been no recurrences or formation of persistent seromas.

“With a full year of follow-up, our research confirms previous findings that this device is safe and effective for radiation delivery, especially compared to other brachytherapy methods,” said Yashar. “Without the ability to customize the dose, other devices can lead to complications, like persistent seroma and skin burns. This applicator was created to overcome these problems, and our research shows it has been successful.”

Breast brachytherapy is a form of Accelerated Partial Breast Irradiation (APBI). Lasting just five days, APBI offers a shorter course of radiation compared to the six weeks required with traditional whole breast irradiation.

“SAVI has the most flexible dose modulation for single-entry APBI applicators and can sculpt the radiation dose to the size and shape of the tumor cavity and the patient’s anatomy, even when only one to two millimeters from normal tissues,” Yashar said.
Without the technical limitations of other methods such as balloon brachytherapy, SAVI substantially increases the number of women who qualify for the benefits of APBI.

Other authors of the poster being presented at ASBS are Daniel Scanderbeg, Anne Wallace, Sarah Blair and Patrick Barna, UC San Diego; and Constantine Mantz, 21st Century Oncology. The SAVI breast brachytherapy applicator is made by Cianna Medical, Inc.

The Moores UCSD Cancer Center is one of the nation’s 41 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer.

For more information: www.cancer.ucsd.edu and www.ciannamedical.com

Related Content

360 Photos | Brachytherapy Systems

This is a 360 degree view inside one of the brachytherapy treatment rooms at Northwestern Medicine's center in ...

Time October 28, 2021
arrow
News | Brachytherapy Systems

August 31, 2021 — iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy ...

Time August 31, 2021
arrow
News | Radiation Oncology

June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional ...

Time June 02, 2021
arrow
News | Brachytherapy Systems, Women's Healthcare

May 19, 2021 — A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells ...

Time May 19, 2021
arrow
News | Brachytherapy Systems

October 26, 2020 — iCAD, Inc. announced the Company will showcase the expanded platform for the Xoft Axxent Electronic ...

Time October 26, 2020
arrow
News | Brachytherapy Systems, Women's Healthcare

September 8, 2020 — Advanced Radiation Therapy has completed the installation of the AccuBoost Digital platform at the ...

Time September 08, 2020
arrow
News | Brachytherapy Systems, Women's Healthcare

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation Therapy, makers of AccuBoost, announced the latest upgrades to the AccuBoost Digital platform. AccuBoost Digital leverages the Planmed Clarity digital mammography system to provide doctors with real-time image-guidance and targeting confidence in the delivery of accelerated partial breast irradiation (APBI) in patients opting for breast conserving therapy (BCT). These upgrades improve the treatment workflow, patient experience and user interface. By design, this non-invasive breast brachytherapy (NIBB) technique is 100 percent adaptive as each treatment fraction is assessed independently and is ideal for the challenges that APBI treatments can present.

Time October 23, 2019
arrow
Videos | Radiation Therapy

ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at the ...

Time February 21, 2019
arrow
News | Brachytherapy Systems, Women's Healthcare

Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System were comparable to those seen in the TARGIT-A and ELIOT trials, according to new results. The results, published in the Annals of Surgical Oncology, came from a long-term study conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, Calif.

Time January 07, 2019
arrow
News | Women's Health

Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to acquire Cianna Medical Inc., headquartered in Aliso Viejo, Calif. The deal structure includes an upfront payment of $135 million with potential earn-out payments of an additional $15 million for achievement of supply chain and scalability metrics, and up to an additional $50 million for achievement of sales milestones.

Time November 14, 2018
arrow
Subscribe Now